A
Axel-R Hanauske
Researcher at Eli Lilly and Company
Publications - 4
Citations - 477
Axel-R Hanauske is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Pemetrexed & Antimetabolite. The author has an hindex of 3, co-authored 4 publications receiving 400 citations.
Papers
More filters
Journal ArticleDOI
Clinical development of new drug-radiotherapy combinations
Ricky A. Sharma,Ruth Plummer,Julie K Stock,Tessa A Greenhalgh,O. Ataman,Stephen Kelly,Robert Clay,Richard Adams,Richard D. Baird,Lucinda Billingham,Sarah Brown,Sean Buckland,Helen Bulbeck,Anthony J. Chalmers,Glen Clack,Aaron N Cranston,Lars Damstrup,Roberta Ferraldeschi,Martin Forster,Golec Julian M C,Russell M Hagan,Emma Hall,Axel-R Hanauske,Kevin J. Harrington,Tom Haswell,Maria A. Hawkins,Timothy M Illidge,Hazel Jones,Andrew S. Kennedy,Fiona McDonald,Thorsten Melcher,James P B O'Connor,John Pollard,Mark P Saunders,David Sebag-Montefiore,Melanie Smitt,John Staffurth,Ian J. Stratford,Stephen R. Wedge +38 more
TL;DR: The CTRad Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer are highlighted.
Journal ArticleDOI
Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors
TL;DR: Folic acid and vitamin B dietary supplementation has been recently introduced into all ongoing trials of pemetrexed, demonstrating that these combination therapies may become important treatment regimens in a variety of cancer types.
Journal ArticleDOI
Pemetrexed safety and dosing strategy.
Clet Niyikiza,Axel-R Hanauske,James J. Rusthoven,A. Hilary Calvert,Robert Allen,Paolo Paoletti,Paul A. Bunn +6 more
TL;DR: Evidence now suggests that reducing total plasma homocysteine levels by supplementation with folic acid and vitamin B(12) leads to a better safety profile for pemetrexed, while not adversely affecting its efficacy.
Reference EntryDOI
Preclinical and Early Clinical Development of Chemotherapeutic Drugs, Mechanism‐Based Agents and Biologics
TL;DR: This chapter provides an overview of the various steps of early clinical development with milestones of the drug-development process, the role of the National Cancer Institute, and the switch to mechanism-based drug development.